Multiple sclerosis lymphocytes upregulate A2A adenosine receptors that are antiinflammatory when stimulated

European Journal of Immunology

Volumn 43, Issue 8, 2013, Pages 2206-2216

  Vincenzi, Fabrizio ^a   Corciulo, Carmen ^a   Targa, Martina ^a   Merighi, Stefania ^a   Gessi, Stefania ^a   Casetta, Ilaria ^b   Gentile, Mauro ^b   Granieri, Enrico ^b   Borea, Pier Andrea ^a   Varani, Katia ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY HOSPITAL OF FERRARA   (Italy)

Author keywords

A2A adenosine receptors; Human lymphocytes; Multiple sclerosis; Proinflammatory cytokines; Very late antigen 4 (VLA 4)

Indexed keywords

ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; VERY LATE ACTIVATION ANTIGEN 4;

ADULT; ARTICLE; BINDING ASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; LYMPHOCYTE; LYMPHOCYTE PROLIFERATION; MALE; MULTIPLE SCLEROSIS; PATHOGENESIS; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

A2A ADENOSINE RECEPTORS; HUMAN LYMPHOCYTES; MULTIPLE SCLEROSIS; PROINFLAMMATORY CYTOKINES; VERY LATE ANTIGEN 4 (VLA-4);

ADENOSINE A2 RECEPTOR AGONISTS; ADULT; CELL PROLIFERATION; FEMALE; HUMANS; INFLAMMATION; INTEGRIN ALPHA4BETA1; INTERFERON-GAMMA; INTERLEUKIN-17; INTERLEUKIN-1BETA; INTERLEUKIN-6; LYMPHOCYTES; MALE; MULTIPLE SCLEROSIS; NF-KAPPA B; RECEPTOR, ADENOSINE A2A; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 84881501350     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201343314     Document Type: Article

References (43)

1. Saidha, S., Eckstein, C. and Calabresi, P. A., New and emerging disease modifying therapies for multiple sclerosis. Ann. N.Y. Acad. Sci. 2012. 1247: 117-137.
2. Comabella, M. and Khoury, S. J., Immunopathogenesis of multiple sclerosis. Clin. Immunol. 2012. 142: 2-8.
3. Amedei, A., Prisco, D. and D'Elios, M. M., Multiple sclerosis: the role of cytokines in pathogenesis and in therapies. Int. J. Mol. Sci. 2012. 13: 13438-13460.
4. Rodgers, J. M. and Miller, S. D., Cytokine control of inflammation and repair in the pathology of multiple sclerosis. Yale J. Biol. Med. 2012. 85: 447-468.
5. Holman, D. W., Klein, R. S. and Ransohoff, R. M., The blood-brain barrier, chemokines and multiple sclerosis. Biochim. Biophys. Acta 2011. 1812: 220-230.
6. Martínez Gómez, J. M., Croxford, J. L., Yeo, K. P., Angeli, V., Schwarz, H. and Gasser, S., Development of experimental autoimmune encephalomyelitis critically depends on CD137 ligand signaling. J. Neurosci. 2012. 32: 18246-18252.
7. Ghosh, S., Biologic therapies: lessons from multiple sclerosis. Dig. Dis. 2012. 30: 383-386.
8. Castro-Borrero, W., Graves, D., Frohman, T. C., Flores, A. B., Hardeman, P., Logan, D., Orchard, M. et al., Current and emerging therapies in multiple sclerosis: a systematic review. Ther. Adv. Neurol. Disord. 2012. 5: 205-220.
9. Haskó, G., Linden, J., Cronstein, B. and Pacher, P., Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat. Rev. Drug Discov. 2008. 7: 759-770.
10. Gessi, S., Merighi, S., Varani, K. and Borea, P. A., Adenosine receptors in health and disease. Adv. Pharmacol. 2011. 61: 41-75.
11. Ramakers, B. P., Riksen, N. P., van der Hoeven, J. G., Smits, P. and Pickkers, P., Modulation of innate immunity by adenosine receptor stimulation. Shock 2011. 36: 208-215.
12. Ohta, A. and Sitkovsky, M., Methylxanthines, inflammation, and cancer: fundamental mechanisms. Handb. Exp. Pharmacol. 2011. 200: 469-481.
13. Gessi, S., Merighi, S., Fazzi, D., Stefanelli, A., Varani, K., and Borea, P. A., Adenosine receptor targeting in health and disease. Expert. Opin. Investig. Drugs 2011. 20: 1591-1609.
14. 2A adenosine receptor. ScientificWorldJournal 2011. 11: 320-339.
15. Varani, K., Vincenzi, F., Tosi, A., Targa, M., Masieri, F. F., Ongaro, A., De Mattei, M. et al., Expression and functional role of adenosine receptors in regulating inflammatory responses in human synoviocytes. Br. J. Pharmacol. 2010. 160: 101-115.
16. 3 adenosine receptor expression in rheumatoid arthritis: upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release. Arthritis Res. Ther. 2011. 13: R197.
17. Varani, K., Caramori, G., Vincenzi, F., Adcock, I., Casolari, P., Leung, E., Maclennan, S. et al., Alteration of adenosine receptors in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2006. 173: 398-406.
18. 3 adenosine receptor upregulation in rheumatoid arthritis patients by treatment with anti-tumor necrosis factor alpha but not methotrexate. Arthritis Rheum. 2009. 60: 2880-2891.
19. 2A adenosine receptor overexpression and functionality, as well as TNF-alpha levels, correlate with motor symptoms in Parkinson's disease. FASEB J. 2010. 24: 587-598.
20. 2A adenosine receptors in chronic heart failure and cardiac transplantation. FASEB J. 2003. 17: 280-282.
21. 3 adenosine receptors in human colorectal cancer is reflected in peripheral blood cells. Clin. Cancer Res. 2004. 10: 5895-5901.
22. 1 receptor-mediated cytokine expression in peripheral blood mononuclear cells from multiple sclerosis patients. Ann. Neurol. 1999. 45: 633-639.
23. 1 receptor expression on macrophages in brain and blood of patients with multiple sclerosis. Ann. Neurol. 2001. 49: 650-658.
24. 1 adenosine receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis. J. Neurosci. 2004. 24: 1521-1529.
25. Capecchi, P. L., Camurri, A., Pompella, G., Mazzola, A., Maccherini, M., Diciolla, F., Lazzerini, P. E. et al., Upregulation of A2A adenosine receptor expression by TNF-alpha in PBMC of patients with CHF: a regulatory mechanism of inflammation. J. Card. Fail 2005. 11: 67-73.
26. Haskó, G. and Pacher, P., A2A receptors in inflammation and injury: lessons learned from transgenic animals. J. Leukoc. Biol. 2008. 83:447-455.
27. Morello, S., Ito, K., Yamamura, S., Lee, K. Y., Jazrawi, E., Desouza, P., Barnes, P. et al., IL-1 beta and TNF-alpha regulation of the adenosine receptor (A2A) expression: differential requirement for NF-kappa B binding to the proximal promoter. J. Immunol. 2006. 177: 7173-7183.
28. Takahashi, J. L., Giuliani, F., Power, C., Imai, Y., Yong, V. W., Interleukin-1beta promotes oligodendrocyte death through glutamate excitotoxicity. Ann. Neurol. 2003. 53: 588-595.
29. Martins, T. B., Rose, J. W., Jaskowski, T. D., Wilson, A. R., Husebye, D., Seraj, H. S. and Hill, H. R., Analysis of proinflammatory and anti-inflammatory cytokine serum concentrations in patients with multiple sclerosis by using a multiplexed immunoassay. Am. J. Clin. Pathol. 2011. 136: 696-704.
30. Palmer, T. M. and Trevethick, M. A., Suppression of inflammatory and immune responses by the A(2A) adenosine receptor: an introduction. Br. J. Pharmacol. 2008. 153: S27-34.
31. Steinman, L., A molecular trio in relapse and remission in multiple sclerosis. Nat. Rev. Immunol. 2009. 9: 440-447.
32. Meuth, S. G., Göbel, K. and Wiendl, H., Immune therapy of multiple sclerosis-future strategies. Curr. Pharm. Des. 2012. 18: 4489-4497.
33. Rigau, V., Mania, A., Béfort, P., Carlander, B., Jonquet, O., Lassmann, H., Camu, W. et al., Lethal multiple sclerosis relapse after natalizumab withdrawal. Neurology 2012. 79: 2214-2216.
34. 2A adenosine receptors inhibits expression of alpha 4/beta 1 integrin (very late antigen-4) on stimulated human neutrophils. J. Leukoc. Biol. 2004. 75: 127-134.
35. Yan, J. and Greer, J. M., NF-kappa B, a potential therapeutic target for the treatment of multiple sclerosis. CNS Neurol. Disord. Drug Targets 2008. 7: 536-557.
36. 2A adenosine receptor signaling in lymphocytes and the central nervous system regulates inflammation during experimental autoimmune encephalomyelitis. J. Immunol. 2012. 188: 5713-5722.
37. 2A receptor exacerbates brain damage in mice with experimental autoimmune encephalomyelitis. J. Neurochem. 2012. 123: 100-112.
38. Xu, J., Guo, S., Jia, Z., Ma, S., Li, Z. and Xue, R., Additive effect of prostaglandin E(2) and adenosine in mouse experimental autoimmune encephalomyelitis. Prostaglandins Other Lipid Mediat. 2013. 100-101C: 30-35.
39. McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H. P., Lublin, F. D., McFarland, H. F. et al., Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 2001. 50: 121-127.
40. García-Bernal, D., Wright, N., Sotillo-Mallo, E., Nombela-Arrieta, C., Stein, J. V., Bustelo, X. R. and Teixidó, J., Vav1 and Rac control chemokine-promoted T lymphocyte adhesion mediated by the integrin alpha4beta1. Mol. Biol. Cell. 2005. 16: 3223-3235.
41. 3 receptors are overexpressed in pleura from patients with mesothelioma and reduce cell growth via Akt/nuclear factor-κB pathway. Am. J. Respir. Crit. Care Med. 2011. 183: 522-530.
42. 3 adenosine receptors. Mol. Pharmacol. 2000. 57: 968-975.
43. 2B receptors. Biochem. Pharmacol. 2005. 70: 1601-1612.